Investigating the appearance of anti-JC CD4+ and CD8+ lymphocytes through ELISPOT is feasible, with an underlying AML diagnosis and recipient age being reported as risk factors negatively linked to the establishment of an antiviral status (141). This evidence concerns the gene CD8A and acute myeloid leukemia.